| abstract |
The present invention relates to a compound of formula (I) or a pharmaceutically acceptable salt thereof, a signal transduction pathway inhibitor, a tumor immunotherapeutic agent, an agent that inhibits a BCL2 family protein, an agent that inhibits Mcl-1. From the group consisting of various agents selected from: a proteasome inhibitor, a poly (ADP-ribose) polymerase (PARP) inhibitor, an aromatase inhibitor, a conventional cytotoxic agent, or abiraterone, ARN-509 and MYC inhibitor It relates to a pharmaceutical composition comprising a combination with at least one second agent selected. |